Latest broker research reports from ICICI Securities Limited buy, sell, hold, neutral recommendations along with
share price targets forecast and upside.
- This broker has downgraded this stock from it's previous report. (eg. - Buy->Hold)
- Broker has maintained previous recommendation but reduced share price target.
- This broker has upgraded this stock from it's previous report.(eg. - Sell->Hold)
- Broker has maintained previous recommendation but increased share price target.
Hindalco’s (HNDL) Q4FY25 performance was ahead of our/consensus estimates. Consolidated EBITDA rose 44% YoY to INR 96bn, mainly due to upstream aluminium (Al) division.
Petronet LNG (PLNG) reported 16%/13% YoY/QoQ increase in adj. EBITDA to INR 12.8bn and +21%/+19% YoY/QoQ change in adj. PAT to INR 8.9bn. Reported PAT was INR 10.7bn with an INR 2.3bn reversal of UoP provision.
ACME reported a strong set of numbers – revenue grew 65% YoY to ~INR 5bn, EBITDA surged 117% YoY to INR 4.4bn with healthy EBITDA margin of ~90%, adj. PAT stood at INR 1.4bn (vs. INR 0.5bn loss in Q4FY24.
NCC reported a revenue of INR 193bn, flat YoY despite having a book-to-bill ratio of 3.7x. EBITDA and PAT for the year were down 5% YoY each, at INR 175bn and INR 8bn, respectively.
INOX reported single digit growth in profit in 9MFY25 owing to trade headwinds. However, it finished the year on a strong note. It recovered lost ground with revenue growth of 34% YoY to INR3.7bn and profit growth of 49% YoY to INR 655m in Q4.
GR Infra continues to tread water on order inflow front, with total OI of INR 140bn in FY25 & FY24 combined - matching FY23’s tally as the ordering in roads remained subdued.
BHEL is the poster child of the Indian thermal power industry. India has recognised the need for building new base load plants despite energy transition.
South Indian Bank (SIB) reported better-than-expected Q4FY25 PAT of INR 3.4bn (up 19% YoY; 8% beat), driven by other income. It sustained ~1% RoA for seventh consecutive quarter with FY25 RoA at 1.06%.
Abbott India’s (Abbott) revenue grew 12% YoY ahead of most MNCs (avg. growth of ~10% YoY and IPM growth of ~8% YoY in Q4FY25). Abbott’s growth was aided by healthy traction in its own brands along with key brands of Novo Nordisk like Rybelsus and Ryzodeg.